# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
nours per response	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Res	sponses	8)													
1. Name and Address of Reporting Person * GERSHELL LELAND			2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306			3. Date of Earliest Transaction (Month/Day/Year) 07/17/2015						r (give title bele		Other (specify b	elow)			
(Street) NEW YORK, NY 10022									5. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(City)	111 1	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned						Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, it any (Month/Day/Year		ate, if Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			d 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amoun	(A) or (D)	Price		or Indired (I) (Instr. 4)		(I)	(Instr. 4)
Common Stock value	k, \$0.0	001 par	07/17/2015			P		1,000	A S	\$ 7.5	18,860			D	
						es Acquire	d, Di	sposed o	of, or Bene	eficial	·	OWB COL	idoi numb	ei.	
1. Title of Derivative Conversion Date Conversion or Exercise (Month/Day/Year) any			Derivative Securities Acquire e.g., puts, calls, warrants, op 4. 5. Number tte, if Transaction of				r 6. Date Exercisable and Expiration Date (Month/Day/Year)  (Month/Day/Year)			citly Owned  Citle and lount of Derivative		9. Number of	of 10. Ownersl Form of	(Instr. 4)	
				_		of (D) (Instr. 3, 4, and 5)					Amount		Transaction (Instr. 4)		
				Co	ode V	(A) (D)	Date Exe	e rcisable	Expiration Date	Title	or Number of Shares				
Reporting	g O	wners													
Reporting Owner Name / Address			Relationships												
GERSHELL LELAND			Director	10% Ow	ner	Officer			Othe	er					

### **Signatures**

/s/ Leland Gershell	07/17/2015
**Signature of Reporting	Date

509 MADISON AVE., STE 306 NEW YORK, NY 10022

C/O TONIX PHARMACEUTICALS HOLDING CORP

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Chief Financial Officer

